ClariVest Asset Management’s Nurix Therapeutics NRIX Stock Holding History

ClariVest Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.32M	Hold	63,149	–	–	0.13%	208
2024 Q2	$1.32M	Buy	63,149 +1,766	+3%	+$27.5K	0.13%	208
2024 Q1	$902K	Buy	61,383 +115	+0.2%	+$1.24K	0.09%	288
2023 Q4	$632K	Buy	61,268 +1,451	+2%	+$9.95K	0.04%	337
2023 Q3	$470K	Hold	59,817	–	–	0.03%	348
2023 Q2	$597K	Buy	59,817 +10,803	+22%	+$110K	0.03%	327
2023 Q1	$436K	Sell	49,014 -86	-0.2%	-$896	0.02%	397
2022 Q4	$539K	Sell	49,100 -600	-1%	-$7.24K	0.03%	375
2022 Q3	$648K	Hold	49,700	–	–	0.03%	321
2022 Q2	$630K	Buy	+49,700	New	+$563K	0.03%	348

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

ClariVest Asset Management's NRIX Position: Q3 2024 in Review

ClariVest Asset Management held its Nurix Therapeutics (NRIX) position steady in Q3 2024 at 63,149 shares worth $1.32M. The position accounts for 0.13% of the portfolio, ranked #208.

ClariVest Asset Management first reported a position in NRIX in Q2 2022 and has held it in 10 quarters since. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

ClariVest Asset Management held 63,149 shares of Nurix Therapeutics worth $1.32M as of Q3 2024.
ClariVest Asset Management left its Nurix Therapeutics share count unchanged in Q3 2024.
Nurix Therapeutics made up 0.13% of ClariVest Asset Management's portfolio in Q3 2024, its #208 holding.
ClariVest Asset Management first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 10 quarters since.
172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.